Compare · NBIX vs VIGL

NBIX vs VIGL

Side-by-side comparison of Neurocrine Biosciences Inc. (NBIX) and Vigil Neuroscience Inc. (VIGL): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both NBIX and VIGL operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
  • NBIX carries a market cap of $15.85B.
  • NBIX has hit the wire 12 times in the past 4 weeks while VIGL has been quiet.
  • NBIX has more recent analyst coverage (25 ratings vs 11 for VIGL).
MetricNBIXVIGL
Company
Neurocrine Biosciences Inc.
Vigil Neuroscience Inc.
Price
-
-
Market cap
$15.85B
-
1M return
+7.29%
-
1Y return
+10.62%
-
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ
NASDAQ
IPO
1996
2022
News (4w)
12
0
Recent ratings
25
11
NBIX

Neurocrine Biosciences Inc.

Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric-based diseases and disorders in the United States. The company offers INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia; ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis pain; and ORIAHNN, a GnRH antagonist for the management of heavy menstrual bleeding associated with uterine fibroids. Its product candidates in clinical development include valbenazine, which is in Phase III clinical trial for the treatment of chorea in Huntington's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients, as well as other indications, such as adult focal epilepsy; NBI-827104, an orally active and brain penetrating T-type calcium channel blocker for treating rare pediatric epilepsy and other indications; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBI-1065844, a D-amino acid oxidase inhibitor for the treatment of negative symptoms of schizophrenia; NBI-1065845, an alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid potentiator for the treatment of resistant depression; and NBI-1065846, a G protein-coupled receptor 139 agonist for treating anhedonia in depression. It has collaborations and agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.

VIGL

Vigil Neuroscience Inc.

Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.

Latest NBIX

Latest VIGL